Alan joined Sanofi on 1st October 2016 as Executive Vice President Consumer Healthcare and as a member of the Sanofi Executive Committee.
Joining from Bayer, where he most recently served as Global President, Bayer Medical Care, Alan is responsible for building and maintaining Sanofi’s leading position in Consumer HealthCare (CHC), which was set up as one of the five strategic business units in the company in January 2017.
A British national from Scotland, Alan has more than 30 years of marketing and general management experience in the Consumer Health and Medical Device fields, beginning with Stafford Miller/Block Drug (now part of GSK), before joining Merrell Dow (now Sanofi), then the London Rubber Company (now Reckitt Benckiser).
In 1992, he joined Roche Consumer Health and rose up through the company, holding roles of increasing scope and responsibility namely in the UK, South Africa and finally Asia Pacific between 2001-2004. Following Bayer’s acquisition of the Roche Consumer Health business in 2004, Alan was a key member of the integration team, then continued to build his international expertise in key operational roles as Region Head for Asia Pacific 2004-2007 and subsequently Europe 2007-2010. In 2010 he transferred to the medical device business of Bayer as Global President for Bayer Medical Care.
Alan holds a BA in International Marketing from Thames Polytechnic in London and has completed various executive and leadership development programs at London, Harvard and Columbia Business Schools, as well as INSEAD (Asia). He currently sits on the Board of Directors of the World Self-Medication Industry (WSMI) and was appointed to their Executive Committee in November 2016. He is also committed to a number of non-profit organisations including being on the Board of African Leadership Foundation. He was appointed as a GlobalScot by the Scottish Government in 2011.
Alison van Wyk
Head of Professional Services, Green Cross Health
Alison has been with Green Cross Health as Head of Professional Services since October 2010. She has a background in nursing and has many years’ sales, marketing and senior management experience within the pharmaceutical, medical device and healthcare supply chain markets both within New Zealand and internationally.
Alison has been actively involved over the last 7 years in the successful reclassifications of vaccines (to prevent against Influenza, Whooping Cough, Shingles and Meningococcal disease), as well as Dukoral, Trimethoprim, Adapalene and most recently Oral Contraceptives. She has also been a key leader in helping to develop innovative models of care that promote pharmacists to operate at the top of their scope of practice. Alison has a passion for making more health services conveniently accessible to local communities through community pharmacy and raising the profile of community pharmacists as a key member of the primary health care team. Alison was a finalist in the 2015 Woman of Influence awards and has won a number of awards recognizing her efforts in the area of medicines reclassification.
Andy Tisman is Global Senior Principal, Consumer Health at QuintilesIMS, responsible for leading QI Consumer Health Consulting and Services globally. Andy joined QI in 2005 with a strong industry and consulting background.
He has over 15 years consulting experience across both OTC/CHC and pharma. Andy has successfully led many strategic consulting and operational projects in most major geographies. Leads QuintilesIMS Consumer Health C&S and global Consumer Health Consulting & Services Community. Andy also has extensive OTC/CHC & pharma marketing/marketing management experience from over 15 years with SmithKline Beecham in local and international (pan-European and global) roles. Andy speaks regularly at industry events and publishes extensively on CHC and OTC issues
Andy Tisman graduated with a Law degree with from the University of Leeds.
Andy’s areas of expertise include, strategy development, including global, regional & local strategy; Commercial Effectiveness, Go-to-Market & Commercial Models; Market entry/brand launch; Rx/OTC Switch.
Andy’s relevant experiences includes working extensively on OTC strategy projects globally, with experience in both developed and emerging geographies and he has a special interest in evolving trends and implications on market evolution.
More information coming soon.
Senior Research Fellow, Macquarie University Centre for the Health Economy (MUCHE)
Dr Parkinson is a Senior Research Fellow at the Macquarie University Centre for the Health Economy. Her expertise is in pharmaceutical policy in Australia, conducting and reviewing economic evaluations of healthcare interventions and technologies, and analysing linked administrative data to inform economic evaluations. Dr Parkinson leads a team of researchers conducting evaluations of submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) and researching economic evaluation methodology. She is a lecturer in health economics to students undertaking the Macquarie University Masters of Public Health and regularly teaches short courses on economic evaluation. She is currently a member of the Ezetimibe Review Reference Group for the Australian Government Department of Health (2016-2017), and was an executive member of the Australian Health Economics Society (AHES) committee (2012-2016). In 2015-2016 she was acting secretary and was involved with organising the 2015 AHES conference. She is currently a local co-organiser of the 2017 AHES conference. She has published numerous journal articles and publications, and has received several awards for her research, including the UTS Chancellor’s List award in 2016 and the UTS Research Excellence Through Partnership award in 2013.
Brian McNamara was appointed as CEO, GSK Consumer Healthcare in September 2016. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health with a portfolio of some of the world’s most trusted and best-selling brands which include Sensodyne, Voltaren, Horlicks and Panadol.
Brian joined GSK in March 2015, as Head of Europe and Americas for GSK Consumer Healthcare, following the creation of a Joint Venture between GSK and Novartis. Previously, as head of Novartis’s OTC division, Brian was a driving force behind the formation of the joint venture and the development of the 3 Year JV strategic and operational plan.
Brian joined Novartis in 2004 as Senior Vice President of the North America OTC business. Brian began his career at Procter and Gamble.
Brian is a board member of the World Self-Medication Industry Association (WSMI) and was previously a Board Member and Chairman of the Economic Affairs Committee, Association for Europe Self-Medication Association (AESGP) and Board Member and Vice Chairman, Consumer Health Products Association (CHPA).
Brian earned an undergraduate degree in Electrical Engineering from Union College in Schenectady, New York and an MBA in Finance from University of Cincinnati.
Head Graduate School of Health, UTS Graduate School of Health
Professor S.I. (Charlie) Benrimoj B.Pharm (Hons), Ph.D. F.P.S., FRPSGB, FFIP is Head of the Graduate School of Health University of Technology Sydney 2011 to present). He was the Foundation Professor of Pharmacy Practice, Dean of the Faculty of Pharmacy and Pro-Vice Chancellor (Strategic Planning) University of Sydney. He is a visiting professor at the University of Granada. He graduated with B. Pharm. (Hons) 1976, followed by completion of a Ph.D. 1980, University of Bradford, U.K. His research interests encompass the future of community pharmacy and professional cognitive pharmaceutical services from community pharmacy. These include the provision of drug information to consumers, clinical interventions, patient medication reviews, disease state management systems, Pharmacy and Pharmacist only medications, change management and international pharmacy practice. Research interests involve the clinical, economic and implementation aspects of cognitive pharmaceutical services from community pharmacy in current and emerging health care systems. He has published over 200 papers in refereed journals, 24 major research reports and presented and co-authored 200 conference presentations. He has co-authored a book “Community Pharmacy: Strategic Change Management” (2007). He was the Australian Pharmacist of the year in 2000. He was awarded the Andre Bedat 2010 by International Pharmacy Federation (FIP). He was elected a Fellow of three distinguished international and national societies in 2008 – Pharmaceutical Society of Australia, 2008 – Royal Pharmaceutical Society of Great Britain, 2007 – International Pharmacy Federation.
More information coming soon.
Lecturer, Griffith University
Principal, Edwin Hemwall LLC Consulting Services
Edwin (Ed), based in the Philadelphia USA area, is an independent consultant in nonprescription drug development and self-care. His prior industry career spanned nearly 35 years in a range of clinical and regulatory leadership roles with Merck (MSD), J&J, GSK and Bayer.
Ed first became known as an expert in Rx-to-OTC switch through his role in the first-in-class switch of Pepcid AC in 1995 followed by other US and global switches, most recently with the US switch of Oxytrol for over-active-bladder in 2013. He has published and lectured as a Switch and Self-Care advocate. In recent years Ed has served on the US FDA’s Clinical Pharmacology and Pharmaceutical Sciences Advisory Committee, the Board of Directors of the U.S. Consumer Healthcare Products Association (CHPA), as Chair of CHPA’s Regulatory and Scientific Affairs Committee, as co-chair of the WSMI Switch Working Group and as an editor for the Journal Self-Care. He holds BS, MS and PhD degrees in biochemistry and pharmacology.
Dr. Eric Brass received his M.D. and Ph.D. (Pharmacology) from Case Western Reserve University. After holding positions at the University of Colorado and Case Western Reserve University, Dr. Brass moved to the UCLA School of Medicine as Chairman of the Department of Medicine at Harbor-UCLA Medical Center. He is currently Professor Emeritus of Medicine, David Geffen School of Medicine at UCLA. Dr. Brass has interests in drug discovery, development and regulation, with a particular focus on prescription to OTC switches. He is a past Chair of the FDA’s Nonprescription Drugs Advisory Committee. Dr. Brass has authored over 180 scientific papers.
Head of the Consumer Care Division, Bayer Consumer Health
Mann was born in Vereeniging, South Africa on October 11, 1958. She holds a degree in Analytical Chemistry and a Marketing Management Diploma from the Institute of Marketing Management in Johannesburg, South Africa.
She began her career in 1982 as a medical representative at Eli Lilly & Company in South Africa. This was followed by positions in Marketing at Johnson & Johnson and Lederle Laboratories. In 1992, she became head of the Lederle pharmaceutical business in South Africa before joining Wyeth as Managing Director for South Africa and Sub-Equatorial Africa in 1994. She then held positions of increasing responsibility at the company through 2009. In 2003, she was appointed Managing Director of Wyeth in Australia and New Zealand, where she introduced a range of significant medicines and nutritionals.
In April 2009, she became Senior Vice President for the global Nutrition business. Following the acquisition of Wyeth by Pfizer, Mann moved to the United States, where she was President and General Manager of Pfizer’s Nutrition Division and a member of the company’s Senior Management Team. In March 2011, she joined Bayer HealthCare as head of the Consumer Care Division and was appointed to the Bayer HealthCare Executive Committee at the same time.
Erica Mann has held executive positions in various industry organizations, including the South African Pharmaceutical Manufacturers’ Association (PMA), Medicines Australia and the International Association of Infant Food Manufacturers. She is the immediate past chair of the World Self Medication Industry Association, which represents the interests of the global nonprescription (over-the-counter, OTC) medicines industry.
Erica Mann has two adult children.
Director General, Association of the European Self-Medication Industry (AESGP)
Dr. Hubertus Cranz has Masters’ degrees in Pharmacy and Economics and obtained a Doctorate in Natural Sciences at the University of Kiel, Germany. After taking part in different trainee programmes in pharmacies and the pharmaceutical industry (Ciba, Bayer), he worked for the Institute for Health System Research in Kiel, a collaborating centre of the World Health Organization (WHO), and for the German Association of the Pharmaceutical Industry (BPI) in Frankfurt. Afterwards, he became Director General of AESGP and established an organization in Brussels representing the full range of the European consumer health industry.
Postdoctoral Researcher, Alpen-Adria-Universitaet Klagenfurt, Austria
Dr Isabell Koinig is a Postdoctoral Researcher at the Department of Media and Communications at the Alpen-Adria-Universitaet Klagenfurt, Austria. She finished her dissertation investigating how different pharmaceutical advertising appeals are received in a cross-cultural context as well as well as their potential to foster consumer self-empowerment. Her most recent publications examine how CSR appeals are perceived as part of health communication messages as well as the influence health-related variables exercise on consumers’ attitudes towards pharmaceutical advertising. Besides health communication, Isabell Koinig’s research interests concern the areas of intercultural advertising, organizational communication, CSR reporting as well as media and convergence management.
Jolanta Bilińska – Plenipotentiary of director of Development and Social Communication at City Medical Centre dr. K. Jonscher in Lodz, till November 2014 National Health Fund- Lodz, Head of the Department of International Cooperation.
Mrs Jolanta Bilińska has M.A. in Clinical Psychology. She used to diagnose hospitalised children and teenagers with personal disorders. In early 90”s she started working for regional newspaper – Dziennik Łódzki. She published almost 2000 articles concerning medical issues and politics. She was mostly interested in matters relating to patients’ rights and the way they are observed in health care system. She also raised patients’ awareness of the health care system .
Since the year 2004 she has performed the function of coordinator concerning European Union in National Health Fund in Łódź. Since 2005 she has been the champion leader in World Alliance for Patient Safety. In 2006 she established Patient Safety Foundation. Its main aim is to promote safety measures in health service as well as to involve patients in the process of treatment, The foundation cooperates with the Ministry of Health, WHO officer and another non-governmental organization which are regarding patients’ matters. She is an expert in Public Health from 2009, she is also a IAPO chair of the board from 2015 (International Alliance of Patients Organizations).
Health Economist, Evidence Strategy & Generation, Precision Health Economics
Josh Noone is a senior research scientist at Precision Health Economics and a research faculty member at the University of North Carolina at Charlotte. In his role at PHE Josh consults on the development of health economic and outcomes research programs for industry partners across therapeutic areas specializing in the study of rare and ultra-rare diseases. At UNCC Josh supports the Data Sciences Initiative teaching classes on real world evidence and decision modeling techniques.
Josh holds a PhD in Health Services Research and has presented research at conferences across the US, Canada, and Europe.
Julio Sánchez y Tépoz
Commissioner at the Mexican Regulatory Agency (COFEPRIS)
Julio Sánchez y Tépoz holds a Law Degree from the Free Law School of Puebla, with studies in Economic Development from the Universidad Complutense de Madrid, Spain. He has worked mainly in the management of regulatory bodies such as the Federal Economic Competition Commission, the Federal Consumer Attorney’s Office and COFEPRIS, where he has held various positions.
In 2011, he joined COFEPRIS as Coordinator of Advisors to the Federal Commissioner and was in charge of implementing the comprehensive admnistrative simplification program of the institution.
In july 2012, he was appointed Commissioner of Health pormotion at COFEPRIS, responsible for being the interlocutor with the regulated industry, directing the projects of generic liberation, the emission of innovative molecules and the design of processes to improve the attention to the public.
President of Consumer Health Products, CHP Canada
Karen is the President of Consumer Health Products Canada (CHP Canada); an industry association representing the makers of over-the-counter medicines and natural health products. She joined the association in July 2014 after more than a decade of senior management roles in both the public and private sectors. After Graduating with a Bachelor’s of Applied Science from Ryerson University in 1997, Karen began a nine-year career with Health Canada taking on increasingly senior-level roles in the areas of regulatory and legislative affairs. In 2006, Karen left the public service to pursue opportunities in the private sector. Her most recent roles, prior to joining CHP Canada, were that of: Director of Canadian Regulatory Affairs for NJOY; Vice President of Federal Government Affairs for the Retail Council of Canada; and Director of Payer Strategies for Sanofi Canada.
Karen currently sits on the World Self-Medication Industry Association Board of Directors, Executive & Finance Committees. She is an active member of Health Canada’s Food Expert Advisory Committee and is a past board member of the Canadian Partnership for Consumer Food Safety Education.
Director & Chairman of the Board of Australia Self Medication Industry association (ASMI).
Over 30 years OTC medicines experience in Sales, Marketing, General Management, Regional multi-country Management and Global Strategic (Category Board) experience with mnc’s Boots Healthcare & Reckitt Benckiser plus extensive Industry Association experience including prior period of 10 years ASMI Committee of Management (2 years as President).
Reappointed to ASMI Board late 2015 as independent Director and elected Chairman early 2016.
Also undertakes Consultancy services specializing in Consumer Healthcare, including strategic input to businesses looking at market entry, M&A, new product launches, Rx to OTC switch, channel strategy in the Over The Counter (OTC) medicines sector.
Industry Manager, Consumer Health, Euromonitor International
As Consumer Health Industry Manager, Matt oversees the research and analysis of the industry and leads a team of experts in 80 markets worldwide. Prior to this role, Matt was the Head of Institutional Channels, where he analysed the changing global healthcare landscape and its effects on the B2B marketplace for goods and services.
He has worked in market research since 2011, including within the Euromonitor Consumer Health system and holds a master’s degree from the Johns Hopkins School of Advanced International Studies.
Global Director of Client Services, Nicholas Hall
Monica Feldman is a Consumer Health Strategist and Global Director of Client Services at Nicholas Hall Group of Companies. Her past twenty five years of experience include the global head of the consumer health industry vertical at a leading business intelligence firm, executive marketing positions and consulting work at top multinational companies, consulting firms and trade organizations. She has been a speaker at major consumer health events, and is regularly quoted in leading trade press. Mrs. Feldman is an active international advocate in business trade expansion for the life sciences and wellness industries. She works regularly with other thought leaders and members of academia to further opportunities in consumer health. At present she inspires industry peers and is engaged in strategy, research and industry collaboration with a focus on preventive health and self-care initiatives.
Monica holds an MBA degree in International Marketing and Finance from DePaul University in Chicago and is a member of the Advisory Council at the Buck Institute for Research on Ageing.
Mukesh Haikerwal AO
More information coming soon.
Former Chair, World Medical Association (WMA)
Dr Natalie Gauld has over 20 years’ experience in widening consumer access to medicines. She has been involved in nearly all prescription to non-prescription switches in New Zealand since 2004, either on the Medicines Classification Committee (2004-2009), or preparing applications and risk management tools (since 2010). She has been at the forefront of the move from traditional symptomatic treatment of minor self-limiting conditions to non-traditional, complex areas, including disease prevention, chronic conditions and antibiotics. This has seen multiple first-in-world switches, including sildenafil with Douglas Pharmaceuticals in 2014. Her work with Alison Van Wyk from Green Cross Health has been award winning, and their latest reclassification is the oral contraceptive.
Natalie’s switch research comprises qualitative and quantitative projects, including pharmacovigilance and an extensive nine-country study considering international variation in switch. This research has been used internationally to widen access to medicines.
Natalie has a Master of Pharmacy degree from the University of Otago, and a PhD in General Practice from the University of Auckland. She is a Fellow of the Pharmaceutical Society of New Zealand and an Honorary Research Fellow at the University of Auckland. Natalie works internationally in switch and research.
President FIP Community Pharmacy section, International Pharmaceutical Federation (FIP)
Paul has been a practicing community pharmacist for the past thirty-five years.
Paul is currently the President of the Community Pharmacy Section of FIP (The International Pharmaceutical Federation) and a Board member of the FIP Board of Pharmaceutical Practice. Paul is a past President of the Pharmacy Guild of Australia, NSW Branch and a past Vice President of the Pharmacy Guild Nationally.
Paul is a current board member of the Asthma Foundation of Queensland/NSW.
As a community pharmacy representative, Paul has promoted the importance of professional programs delivered via community pharmacy and has been a strong advocate for the expansion of the scope of practice of pharmacists.
Paul has co-authored the recent FIP publication “Pharmacists- as a Gateway to Care” which explores the potential of the Pharmacist in the self-care environment.
More information coming soon.
Director of the Centre for Health Economics Research, UTS CHERE
CEO, International Confederation of Midwives (ICM)
Dr Sally Pairman is Chief Executive of the International Confederation of Midwives (ICM), a role she took in late January 2017 after more than 30 years of work in midwifery practice, education, and regulation in her home country of New Zealand.
Previously, Sally was Professor of Midwifery and Director of Learning and Teaching at Otago Polytechnic, where she was also previously the Head of Midwifery.
She has held several national and international midwifery leadership roles, including a five-year term as President of New Zealand College of Midwives and a nine-year term as the first chairperson of the inaugural Midwifery Council of New Zealand. Sally has co-chaired ICM’s Regulation Standing Committee sonce 2008 and been a member of ICM’s Scientific Professional Programme Committee since 2011.
Sally has contributed to the midwifery academic field with numerous publications, including ‘Midwifery Partnership: a model for practice” and “Women’s Business: the history of the New Zealand College of Midwives 1986-2010” (co-authored with Karen Guilliland). She is co-editor for the Australasian midwifery textbook, “Midwifery: Preparation for Practice”, now in development for its 4th edition.
Throughout her career, Sally has maintained her commitment to promoting midwifery as a strong, autonomous profession and to maintaining choices for women in childbirth services as evidenced through her political and professional activities and through her research and publications. Her services to midwifery were recognised in 2008 when she was made a member of the New Zealand Order of Merit.
President & CEO, Consumer Health Products Association (CHPA)
Scott Melville is the president and chief executive officer of CHPA and leads the organization’s efforts to empower consumer self-care by preserving and expanding choice and availability of consumer healthcare products.
Prior to joining CHPA, Melville served as senior vice president of government affairs and general counsel for the Healthcare Distribution Management Association (now the Healthcare Distribution Alliance), representing pharmaceutical wholesale distributors.
Prior to that role, Melville served in various public affairs and legal roles for the pharmaceutical and biotechnology companies Sterling-Winthrop, Hoffmann- LaRoche, and Cephalon. Melville began his professional career as a legislative assistant and appropriations committee associate on the staff of retired U.S. Congressman Jerry Lewis (R-Calif.).
He earned his bachelor’s degree from Bucknell University, and his juris doctorate from George Mason University School of Law. He serves on the boards of the World Self-Medication Industry, the CHPA Educational Foundation, and the Food & Drug Law Institute.
Yoshihiro Miwa is President and CEO of Kowa Company, Ltd. He is one of those involved in the foundation of Japan Federation of Self-Medication Industries (JFSMI) and Asia-Pacific Self-Medication Industry (APSMI). He is also Chairman of JFSMI (since May 2016), appointed as Royal Thai Honorary Consul-General of Nagoya (since May 2016), Member of the Policy Board of Japan Business Federation (since June 2012), Chairman of Japan Self-Medication Industry (JSMI) (from May 2007 to May 2011), Director of World Self-Medication Industry (WSMI) (since June 2006), Chairman of Divisional Assembly, International Trade, Nagoya Chamber of Commerce and Industry, (since February 2005), Director of Federation of Pharmaceutical Manufacturer’s Association of Japan (since May 2002), Executive Director of Japan Foreign Trade Council Inc. (since August 1996), Director of Japan Pharmaceutical Manufacturers Association (since August 1995).
Zephanie Jordan is Vice President Global Regulatory Affairs at RB. Her career spans 25 years in the consumer health industry including roles at P&G, SmithKline Beecham, Boots Healthcare, J&J and the Australian-Self Medication Industry.
Zephanie has long been an advocate of consumer centric strategy and product development. She also strongly supports the critical role that self-care plays in sustainable healthcare, both in terms of the social and economic benefits to society through consumer empowerment, and in reducing pressures on healthcare systems around the world.
Zephanie holds qualifications in Food, Pharmaceutical and Wine science from Australian universities.